Skip to content
Screener

Net Income at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$8.65M-24.4%
Opko Health logo
Opko HealthOPK
-$8.42M+94.3%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
-$4.28M-477%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$67.23M-1,047%
Roivant Sciences logo
Roivant SciencesROIV
-$189.84M+15.0%
CorMedix logo
CorMedixCRMD
$38.6M+87.0%

Segments

By segment

See full
Reportable Segment Aggregation Before Other Operating-$17.58M+76.8%

Other financials

Income statement

See full
Revenue$74.3M+88.0%
Gross profit$59.2M+71.7%
Operating income-$4.0M+93.4%
EPS (diluted)-$0.21+80.0%

Balance sheet

See full
Cash & equivalents$182.5M+22.0%
Total debt$167.1M-18.9%
Total equity-$344.3M+15.2%
Total assets$327.1M+30.7%

Cash flow

See full
Operating cash flow-$1.9M+96.9%
CapEx$44.0K-54.6%
Free cash flow-$2.0M+96.9%

Valuation

See full
Market cap$691.7M-5.2%
Enterprise value$676.34M-13.9%
P/S2.9×-3.5×

Profitability

See full
Gross margin82.9%-4.0pp
Operating margin-17%-8.2pp
Net margin-41.3%-19.1pp
FCF margin-15.4%-7.4pp

Returns & leverage

See full
Return on equity-147.9%
Debt / equity5.6×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Phathom Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 7:05 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324867
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other (expense) income:
Interest income1,5101,7873,2464,427
Interest expense(15,103)(17,518)(30,900)(35,588)
Other expense, net(24)(155)(855)(179)
Total other expense(13,617)(15,886)(28,509)(31,340)
Net loss and comprehensive loss$(17,582)$(75,810)$(47,951)$(170,126)
Net loss per share, basic and diluted$(0.21)$(1.05)$(0.58)$(2.36)
Weighted-average shares of common stock outstanding, basic and diluted83,747,10472,466,20382,903,54772,219,179

Item 1. Financial Statements (unaudited)

FAQ

What is Phathom Pharmaceuticals, Inc.'s net income?
Phathom Pharmaceuticals, Inc. (PHAT) reported net income of -$17.58M in Q2 2026.
How has Phathom Pharmaceuticals, Inc.'s net income changed year-over-year?
Phathom Pharmaceuticals, Inc.'s net income increased by 76.8% year-over-year, from -$75.81M to -$17.58M.
What is the long-term trend for Phathom Pharmaceuticals, Inc.'s net income?
Over 4 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s net income has grown at a 11.4% compound annual growth rate (CAGR), from -$143.88M to -$221.25M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Phathom Pharmaceuticals, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude